Acid Loading Unmasks Glucose Homeostatic Instability in Proximal-Tubule-Targeted Insulin/Insulin-Like-Growth-Factor-1 Receptor Dual Knockout Mice.


Journal

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
ISSN: 1421-9778
Titre abrégé: Cell Physiol Biochem
Pays: Germany
ID NLM: 9113221

Informations de publication

Date de publication:
18 Jul 2020
Historique:
accepted: 11 07 2020
entrez: 18 7 2020
pubmed: 18 7 2020
medline: 13 1 2021
Statut: ppublish

Résumé

Metabolic syndrome and type 2 diabetes are associated with some degree of acidosis. Acidosis has also been shown to upregulate renal gluconeogenesis. Whether impaired insulin or insulin-like-growth factor 1 receptor (IGF1) signaling alter this relationship is not known. Our aim was to determine the effects of deletion of insulin and IGF1 receptors (Insr and Igf1r) from renal proximal tubule (PT) on the gluconeogenic response to acidosis. We developed a mouse model with PT-targeted dual knockout (KO) of the Insr/Igf1r by driving Cre-recombinase with the gamma-glutamyl transferase (gGT) promoter. Male and female mice were maintained as control or acidotic by treatment with NH Acidosis in both genotypes increased renal expression of phosphoenolpyruvate carboxykinase (PEPCK) and fructose-1-bisphosphatase (FBP1), but not glucose-6-phosphatase catalytic subunit (G6PC), which showed significantly lower expression in the KO regardless of treatment. Several differences between KO and WT suggested a protective role for insulin/IGF1 receptor signaling in maintaining relative euglycemia in the face of acidosis. First, the increase in FBP1 with acid was greater in the KO (significant interactive term). Secondly, proximal-tubule-associated FOXO1 and AKT overall protein levels were suppressed by acid loading in the KO, but not in the WT. Robust intact insulin signaling would be needed to reduce gluconeogenesis in PT. Third, phosphorylated FOXO1 (pS256) levels were markedly reduced by acid loading in the KO PT, but not in the WT. This reduction would support greater gluconeogenesis. Fourth, the sodium-glucose cotransporter (SGLT1) was increased by acid loading in the KO kidney, but not the WT. While this would not necessarily affect gluconeogenesis, it could result in increased circulatory glucose via renal reabsorption. Reduced susceptibility to glucose-homeostatic dysregulation in the WT could potentially relate to the sharp (over 50%) reduction in renal levels of sirtuin-1 (SIRT1), which deacetylates and regulates transcription of a number of genes. This reduction was absent in the KO. Insulin resistance of the kidney may increase whole-body glucose instability a major risk factor for morbidity in diabetes. High dietary acid loads provide a dilemma for the kidney, as ammoniagenesis liberates α-ketoglutarate, which is a substrate for gluconeogenesis. We demonstrate an important role for insulin and/or IGF1 receptor signaling in the PT to facilitate this process and reduce excursions in blood glucose. Thus, medications and lifestyle changes that improve renal insulin sensitivity may also provide added benefit in type 2 diabetes especially when coupled with metabolic acidosis.

Sections du résumé

BACKGROUND/AIMS OBJECTIVE
Metabolic syndrome and type 2 diabetes are associated with some degree of acidosis. Acidosis has also been shown to upregulate renal gluconeogenesis. Whether impaired insulin or insulin-like-growth factor 1 receptor (IGF1) signaling alter this relationship is not known. Our aim was to determine the effects of deletion of insulin and IGF1 receptors (Insr and Igf1r) from renal proximal tubule (PT) on the gluconeogenic response to acidosis.
METHODS METHODS
We developed a mouse model with PT-targeted dual knockout (KO) of the Insr/Igf1r by driving Cre-recombinase with the gamma-glutamyl transferase (gGT) promoter. Male and female mice were maintained as control or acidotic by treatment with NH
RESULTS RESULTS
Acidosis in both genotypes increased renal expression of phosphoenolpyruvate carboxykinase (PEPCK) and fructose-1-bisphosphatase (FBP1), but not glucose-6-phosphatase catalytic subunit (G6PC), which showed significantly lower expression in the KO regardless of treatment. Several differences between KO and WT suggested a protective role for insulin/IGF1 receptor signaling in maintaining relative euglycemia in the face of acidosis. First, the increase in FBP1 with acid was greater in the KO (significant interactive term). Secondly, proximal-tubule-associated FOXO1 and AKT overall protein levels were suppressed by acid loading in the KO, but not in the WT. Robust intact insulin signaling would be needed to reduce gluconeogenesis in PT. Third, phosphorylated FOXO1 (pS256) levels were markedly reduced by acid loading in the KO PT, but not in the WT. This reduction would support greater gluconeogenesis. Fourth, the sodium-glucose cotransporter (SGLT1) was increased by acid loading in the KO kidney, but not the WT. While this would not necessarily affect gluconeogenesis, it could result in increased circulatory glucose via renal reabsorption. Reduced susceptibility to glucose-homeostatic dysregulation in the WT could potentially relate to the sharp (over 50%) reduction in renal levels of sirtuin-1 (SIRT1), which deacetylates and regulates transcription of a number of genes. This reduction was absent in the KO.
CONCLUSION CONCLUSIONS
Insulin resistance of the kidney may increase whole-body glucose instability a major risk factor for morbidity in diabetes. High dietary acid loads provide a dilemma for the kidney, as ammoniagenesis liberates α-ketoglutarate, which is a substrate for gluconeogenesis. We demonstrate an important role for insulin and/or IGF1 receptor signaling in the PT to facilitate this process and reduce excursions in blood glucose. Thus, medications and lifestyle changes that improve renal insulin sensitivity may also provide added benefit in type 2 diabetes especially when coupled with metabolic acidosis.

Identifiants

pubmed: 32678535
doi: 10.33594/000000248
pmc: PMC7414422
mid: NIHMS1615008
doi:

Substances chimiques

Forkhead Box Protein O1 0
Foxo1 protein, mouse 0
Insulin 0
Slc5a1 protein, mouse 0
Sodium-Glucose Transporter 1 0
Ammonium Chloride 01Q9PC255D
Receptor, IGF Type 1 EC 2.7.10.1
Receptor, Insulin EC 2.7.10.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1
Fructose-Bisphosphatase EC 3.1.3.11
Glucose-6-Phosphatase EC 3.1.3.9
Sirt1 protein, mouse EC 3.5.1.-
Sirtuin 1 EC 3.5.1.-
Phosphoenolpyruvate Carboxykinase (ATP) EC 4.1.1.49
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

682-695

Subventions

Organisme : NIDDK NIH HHS
ID : K01 DK106400
Pays : United States
Organisme : Marriott Foundation Cardiovascular Fellowship
Pays : United States
Organisme : NIH HHS
ID : K01-DK-106400
Pays : United States
Organisme : American Diabetes Association
ID : 1-18-PMF-002
Pays : United States

Informations de copyright

© Copyright by the Author(s). Published by Cell Physiol Biochem Press.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to declare.

Références

Am J Physiol Renal Physiol. 2005 Dec;289(6):F1281-90
pubmed: 16077082
Biochem Biophys Res Commun. 2015 May 22;461(1):154-8
pubmed: 25866180
Am J Physiol. 1998 Jan;274(1):F129-38
pubmed: 9458832
Nat Rev Nephrol. 2017 Jan;13(1):11-26
pubmed: 27941935
Am J Physiol Renal Physiol. 2003 Mar;284(3):F584-93
pubmed: 12556366
J Biol Chem. 2011 Jul 15;286(28):24553-60
pubmed: 21592956
Nature. 1966 Dec 31;212(5070):1589-90
pubmed: 21105520
Cell Physiol Biochem. 2014;34(2):575-89
pubmed: 25116356
Curr Opin Clin Nutr Metab Care. 2001 Jul;4(4):279-85
pubmed: 11458021
Diabetes Care. 2001 Feb;24(2):382-91
pubmed: 11213896
Curr Opin Nephrol Hypertens. 2015 Sep;24(5):463-9
pubmed: 26125647
Pflugers Arch. 1988 Oct;412(6):604-12
pubmed: 3211711
J Biol Chem. 2000 Nov 17;275(46):36324-33
pubmed: 10960473
Kidney Int. 2003 Dec;64(6):2163-71
pubmed: 14633139
Biochem J. 1994 Apr 15;299 ( Pt 2):321-34
pubmed: 8172590
Am J Physiol Renal Physiol. 2018 Aug 1;315(2):F211-F222
pubmed: 29561185
Diabetologia. 2013 Jan;56(1):204-17
pubmed: 23090186
Nature. 2014 Sep 11;513(7517):251-5
pubmed: 25043030
Physiol Rep. 2016 Dec;4(23):
pubmed: 27923977
Cell. 2004 May 14;117(4):421-6
pubmed: 15137936
Cell Mol Life Sci. 2017 Jul;74(14):2537-2545
pubmed: 28220207
J Am Soc Nephrol. 2007 Oct;18(10):2661-71
pubmed: 17855644
Am J Physiol. 1968 Jul;215(1):211-7
pubmed: 5659335
Nature. 2003 May 29;423(6939):550-5
pubmed: 12754525
J Am Soc Nephrol. 2018 Jul;29(7):1799-1809
pubmed: 29712732
J Cell Physiol. 2019 Jun;234(6):8134-8151
pubmed: 30370538
Am J Physiol Renal Physiol. 2007 Jul;293(1):F178-85
pubmed: 17389677
J Biol Chem. 1979 Mar 25;254(6):1875-8
pubmed: 422559
Obesity (Silver Spring). 2010 Mar;18(3):463-9
pubmed: 19730425
Am J Physiol Renal Physiol. 2007 Jan;292(1):F140-7
pubmed: 16896179
Diabetes. 2017 Sep;66(9):2339-2350
pubmed: 28630133
Diabetes Obes Metab. 2012 Jan;14(1):5-14
pubmed: 21955459
J Cell Biochem. 2017 Feb;118(2):276-285
pubmed: 27322100
Am J Physiol Cell Physiol. 2008 Aug;295(2):C475-89
pubmed: 18524944
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11285-90
pubmed: 13679577
J Clin Invest. 1969 Mar;48(3):574-83
pubmed: 5773093
Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1627-38
pubmed: 23908456
Biomed Res Int. 2014;2014:504808
pubmed: 24982885
J Am Soc Nephrol. 2013 Jul;24(8):1209-14
pubmed: 23723425
Am J Physiol Renal Physiol. 2000 Jul;279(1):F46-53
pubmed: 10894786
J Am Soc Nephrol. 2011 Jan;22(1):104-12
pubmed: 20616166

Auteurs

Abdullah Aljaylani (A)

Division of Endocrinology and Metabolism, Department of Medicine, Georgetown University, Washington, D.C., USA.

Maurice Fluitt (M)

Division of Endocrinology and Metabolism, Department of Medicine, Georgetown University, Washington, D.C., USA.

Alexandra Piselli (A)

Division of Endocrinology and Metabolism, Department of Medicine, Georgetown University, Washington, D.C., USA.

Blythe D Shepard (BD)

School of Nursing and Health Studies, Department of Human Science, Georgetown University, Washington, D.C., USA.

Swasti Tiwari (S)

Department of Molecular Medicine & Biotechnology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Utter Pradesh, India.

Carolyn M Ecelbarger (CM)

Division of Endocrinology and Metabolism, Department of Medicine, Georgetown University, Washington, D.C., USA, ecelbarc@georgetown.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH